URGN
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- UroGen submitted an NDA for UGN-103, an investigational treatment for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancerAug 17, 2026
- UroGen received a new U.S. patent allowance extending protection for ZUSDURI and UGN-103 through 2044Jul 15, 2026
- UroGen received FDA clearance for the IND application of UGN-501 for non-muscle invasive bladder cancerJul 8, 2026
- ZUSDURI continued showing durable responses at 36 months in the pivotal ENVISION trialMay 13, 2026
- ENVISION trial results published showing 72.2% response durability at 24 months with ZUSDURIMar 30, 2026